Castle Biosciences vs DocGo
Castle Biosciences reported revenue of $344 million in fiscal 2025, about the same as DocGo's $322 million in fiscal 2025. Castle Biosciences' revenue grew 3.7% in its latest year, and DocGo's fell 47.7%. Castle Biosciences had an operating margin of -12.4%, against -55.3% at DocGo. Free cash flow was $28 million at Castle Biosciences and $30 million at DocGo.
Side by side
| Castle Biosciences | DocGo | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $344M | $322M |
| Revenue growth | 3.7% | −47.7% |
| Revenue growth a year, last 5 years | 40.6% | 27.9% |
| Gross margin | 79.4% | — |
| Operating margin | −12.4% | −55.3% |
| Net margin | −7.0% | −56.6% |
| Free cash flow | $28M | $30M |
| Free cash flow margin | 8.2% | 9.3% |
| Return on capital | −19.1% | −84.6% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $11M |
| Change in diluted share count | −0.9% | −9.5% |
| Last close | $33.41 | $0.17 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $16.6 million | sold $15,334 |
| Piotroski F-score | 4 of 9 | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Castle BiosciencesDocGo
Operating margin
Percent of revenue
Castle BiosciencesDocGo
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Castle BiosciencesDocGo
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Castle Biosciences and DocGo pages.